Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Genes, BRCA1
  • Genes, BRCA2
  • Mutation
  • Ovarian Neoplasms

abstract

  • The current data suggests that BRCA2 mutations confer an overall survival advantage compared with either being BRCA-negative or having a BRCA1 mutation in high-grade serous ovarian cancer. This finding may have important implications for clinical trial design.

publication date

  • August 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3625663

Digital Object Identifier (DOI)

  • 10.1002/cncr.26655

PubMed ID

  • 22139894

Additional Document Info

start page

  • 3703

end page

  • 9

volume

  • 118

number

  • 15